Dysphagia Affecting Quality of Life in Cerebellar Ataxia-a Large Survey.

"Conflict of Interest M. Rönnefarth, N. Hanisch, and A. Mähler declare that they have no conflict of interest. A. U. Brandt is cofounder of and holds shares in Motognosis GmbH and Nocturne GmbH. He is named as inventor on several patent applications regarding retinal image analysis, perceptive computing, and multiple sclerosis biomarkers. M. Endres reports grants from Bayer, BMBF, Corona Foundation, DFG, DZHK, DZNE, EU, and Foundation Leducq and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GSK, Sanofi, Covidien, Novartis, all outside the submitted work. F. Paul is part of the scientific advisory board of Novartis. He reports fees from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire. He is academic editor of PLos One, associate editor of Neurology® Neuroimmunology & Neuroinflammation; he has been advisor to Sanofi–Genzyme, Biogen Idec, MedImmune, Shire and Alexion; he reports funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, Deutsche Forschungsgemeinschaft, Werth Stiftung in Cologne, Bundesministerium für Bildung und Forschung, Arthur Arnstein Stiftung Berlin, EU FP7 Rahmenprogramm, Guthy Jackson Charitable Foundation and National Multiple Sclerosis of the USA. S. Doss received project funding by DFG, BMBF, teva pharma, Actelion, DHAG (Deutsche Heredo Ataxie Gesellschaft) and Ataxia UK as well as speaker honoraria from Actelion."

"Funding Information Open Access funding provided by Projekt DEAL."